Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid μ-agonists in an antinociception assay

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 1, 2003, Pages 301-309

  Sterious, Steven N ^a,b   Walker, Ellen A ^b,c  

^a Temple University   (United States)

^b EINSTEIN MEDICAL CENTER   (United States)

^c LA SALLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; BUPRENORPHINE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETORPHINE; MORPHICEPTIN[3 (N METHYLPHENYLALANINE) 4 DEXTRO PROLINAMIDE]; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALTREXONE; RADIOLIGAND; WATER;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMPETITION; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; TAIL FLICK TEST; WATER TEMPERATURE;

ALKALOIDS; ANALGESICS, OPIOID; ANIMALS; BINDING, COMPETITIVE; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ETORPHINE; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MALE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; PAIN MEASUREMENT; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, OPIOID, MU;

EID: 0037216808     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042093     Document Type: Article

References (41)

1. Abbruscato TJ, Thomas SA, Hruby VJ, and Davis TP (1997) Blood-brain barrier permeability and bioavailability of a highly potent and μ-selective opioid receptor antagonist, CTAP: Comparison with morphine. J Pharmacol Exp Ther 280;402-409.
2. Adams JU, Geller EB, and Adler MW (1994) Receptor selectivity of icv morphine in the rat cold water tail-flick test. Drug Alcohol Depend 35:197-202.
3. Arunlakshana O and Schild H (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
4. Bilsky EJ, Bernstein RN, Wang Z, Sadee W, and Porreca F (1996) Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 277:484-490.
5. Chang KJ, Wei ET, Killian A, and Chang JK (1983) Potent morphiceptin analogs: Structure activity relationships and morphine-like activities. J Pharmacol Exp Ther 227:403-408.
6. Egleton RD, Abbruseato TJ, Thomas SA, and Davis TP (1998) Transport of opioid peptides into the central nervous system. J Pharm Sci 87:1433-1439.
7. Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, and Medzihradsky F (1996) Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther 278:1121-1127.
8. Garner HR, Burke TF, Lawhorn D, Stoner JM, and Wessinger WD (1997) Butorphanol-mediated antinociception in mice: Partial agonist effects and μ-receptor involvement. J Pharmacol Exp Ther 282:1253-1261.
9. Goldstein A and Naidu A (1989) Multiple opioid receptors: Ligand selectivity profiles and binding site signatures. Mol Pharmacol 36:265-272.
10. Grider J and Maklouf G (1991) Identification of opioid receptors on gastric muscle cells by selective receptor protection. Am J Physiol 260:G103-G107.
11. He L and Lee NM (1998) Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. J Pharmacol Exp Ther 285:1181-1186.
12. Hurley RW and Hammond DL (2001) Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal μ opioid receptor agonists after inflammatory injury. J Neurosci 21:2536-2545.
13. Kazmierski W, Wire WS, and Lui G (1988) Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. J Med Chem 31:2170-2177.
14. Kosterlitz HW and Paterson SJ (1980) Characterization of opioid receptors in nervous tissue. Proc R Sac Lond B 210:113-122.
15. Kramer TH, Shook JE, Kazmierski W, Ayres EA, Wire WS, Hruby VJ, and Burks TF (1989) Novel peptidic mu opioid antagonists: Pharmacologic characterization in vitro and in vivo. J Pharmacol Exp Ther 249:544-551.
16. Lange DG, Fujimoto JM, Fuhrman-Lane CL, and Wang RIH (1980) Unidirectional non-cross tolerance to etorphine in morphine-tolerant mice and role of the blood-brain barrier. Toxicol Appl Pharmacol 54:177-186.
17. Liu JG and Prather PL (2001) Chronic exposure to μ-opioid agonists produces constitutive activation of μ-opioid receptors in direct proportion to the efficacy of agonist used for pretreatment. Mol Pharmacol 60:53-62.
18. Maldonado R, Negus SS, and Koob GF (1992) Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta-, and kappa-selective opioid antagonists. Neuropharmacology 31:1231-1242.
19. Medzihradsky F, Emmerson PJ, and Mousigian CA (1992) Lipophilicity of opioids determined by a novel micromethod. J Pharmacol Toxicol 27:67-69.
20. Mundey MK, Ali A, Mason R, and Wilson VG (2000) Pharmacological examination of contractile response of the guinea-pig isolated ileum produced by μ-opioid receptor antagonists in the presence of and following exposure to, morphine. Br J Pharmacol 131:893-902.
21. Negus SS, Burke TF, Medzihradsky F, and Woods JH (1993) Effects of opioid agonists selective for mu, kappa, and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. J Pharmacol Exp Ther 267:896-903.
22. Neil A (1984) Affinities of some common opioid analgesics toward four binding sites in mouse brain. Naunyn-Schmiedeberg's Arch Pharmacol 328:24-29.
23. Onogi T, Minami M, Katao Y, Nakagawa T, Aoki Y, Katsumata S, and Satoh M (1995) DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops. FEBS Lett 357:93-97.
24. Pelton JT, Kazmierski W, Gulya K, Yamamura HI, and Hruby VJ (1986) Design and synthesis of conformationally constrained somatestatin analogues with high potency and specificity for mu opioid receptors. J Med Chem 29:2370-2375.
25. Riba P, Ben Y, Smith AP, Furst S, and Lee NM (2002) Morphine tolerance in spinal cord is due to interaction between μ- and δ-receptors. J Pharmacol Exp Ther 300:265-272.
26. Schiller PW, Nguyen TM, Chung NN, and Lemieux C (1989) Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high mu opioid receptor selectivity. J Med Chem 32:698-703.
27. Shook JE, Lemcke PK, Gehrig CA, Hruby VJ, and Burks TF (1989) Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta, and kappa opioid receptors: Inhibition of diarrhea without constipation. J Pharmacol Exp Ther 249:83-90.
28. Shook JE, Pelton JT, and Burks TF (1987) Pepide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 243:492-500.
29. Szeto HH, Loveleace JL, Fridland G, Soong Y, Fasolo J, Wu D, Desiderio DM, and Schiller PW (2001) In vivo pharmacokinetics of selective μ-opioid peptide agonists. J Pharmacol Exp Ther 298:57-61.
30. Takasuna M, Negus SS, De Costa BR, and Woods JH (1994) Opioid pharmacology of antinociceptive effects of loperamide in mice. Behav Pharmacol 5:189-195.
31. Takemori AE (1974) Determination of pharmocological constants: Use of narcotic antagonists to characterize analgesic receptors, in Narcotic Antagonists (Braude M, Harris L, May E, Smith J, and Villarreal J eds) pp 335-344, Raven Press, New York.
32. Takemori AE and Portoghese PS (1984) Comparative antagonism of mu, kappa and delta agonists. Eur J Pharmacol 104:101-104.
33. Tallarida RJ and Murray RB (1987) Manual of Pharmacological Calculations with Computer Programs. Springer Verlag, New York.
34. Tiano MJ, Walker EA, and Dykstra LA (1998) Cross-tolerance to etorphine differentiates μ-opioid agonists in a rat tail withdrawal assay. Analgesia 3:251-257.
35. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47:848-854.
36. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959-968.
37. 2 analysis in rats treated with either clocinnamox or morphine. Psychopharmacology 125:113-119.
38. Walker EA, Zernig G, and Young AM (1998) In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay. Psychopharmacology 136:15-23.
39. Wang Z, Bilsky EJ, Porreca F, and Sadee W (1994) Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54:PL339-PL350.
40. Xue JC, Chen C, Zhu J, Kunapuli SP, de Riel JK, Yu L, and Liu-Chen LY (1995) The third extracellular loop of the opioid receptor is important for agonist selectivity. J Bio Chem 270:12977-12979.
41. Zar JH (1996) Biostatistical Analysis, 3rd ed. Prentice Hall, Upper Saddle River, NJ.